Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Chief Business Officer | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,056 |
Reported balance
After 2026-09-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-24 · Gift · Disposed 17,100 · Balance 14,056 F1: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| Common StockSEC Table I · non-derivative | IndirectCustodial Account for Child | 20,571 |
Reported balance
After 2026-09-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-24 · Gift · Acquired 5,000 · Balance 20,571 F2: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. |
| Common StockSEC Table I · non-derivative | IndirectCustodial Account for Child | 20,571 |
Reported balance
After 2026-09-24 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-24 · Gift · Acquired 5,000 · Balance 20,571 F3: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. |
| Common StockSEC Table I · non-derivative | IndirectGary Charles Robb TTE Robb Revocable Trust | 39,716 |
Reported balance
Holding disclosure · report date 2026-09-24 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 39,716 F4: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
F3: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.
F4: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2025 Filed Mar 5, 2025 00:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 292 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-032708 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,490 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 292 | $59.07 | $17,248.44 |
DisclosureSEC source: 0000950170-25-032708 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,198 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 3, 2025. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 00:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 250 | $60.58 | $15,145.00 |
DisclosureSEC source: 0000950170-25-032708 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,906 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on February 28, 2025 was used to calculate the withholding obligation. F3 · balance_after: Includes 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:27 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 140,000 | $0.00 Strike: $60.58 | $0.00 |
DisclosureSEC source: 0000950170-25-032708 · ownership.xml · derivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2035-02-28 F8 · derivative.exercise_date: Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| January 27, 2025 Filed Apr 23, 2025 23:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 313 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-057620 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 11,211 F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| January 27, 2025 Filed Apr 23, 2025 23:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 313 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-057620 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 11,211 F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 3,037 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-25-002439 · ownership.xml · derivative · entry 7 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,037 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 3,037 | $3.29 | $9,991.73 |
DisclosureSEC source: 0000950170-25-002439 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 11,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-25-002439 · ownership.xml · derivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,037 Underlying: Common Stock · 11,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 11,000 | $50.50 | $555,551.70 |
DisclosureSEC source: 0000950170-25-002439 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,119 F2 · kind: This transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $50.39 to $50.84 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 11,000 | $3.29 | $36,190.00 |
DisclosureSEC source: 0000950170-25-002439 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 290 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133440 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,119 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 290 | $59.21 | $17,170.90 |
DisclosureSEC source: 0000950170-24-133440 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,829 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on December 2, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| December 02, 2024 Filed Dec 5, 2024 00:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 324 | $57.68 | $18,688.32 |
DisclosureSEC source: 0000950170-24-133440 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,539 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain withholding obligations in connection with the issuance of share upon the vesting of restricted stock units. F2 · price: The closing price on November 29, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 23:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-131176 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,863 F1 · balance_after: Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| November 22, 2024 Filed Nov 26, 2024 23:16 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 2,609 | $56.20 | $146,625.80 |
DisclosureSEC source: 0000950170-24-131176 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,163 F1 · balance_after: Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 23:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 11,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-24-111052 · ownership.xml · derivative · entry 5 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,037 Underlying: Common Stock · 11,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Full exercisable. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 23:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 11,000 | $46.28 | $509,080.00 |
DisclosureSEC source: 0000950170-24-111052 · ownership.xml · nonDerivative · entry 4 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,772 F3 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F2 · balance_after: Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| October 01, 2024 Filed Oct 1, 2024 23:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 11,000 | $3.29 | $36,190.00 |
DisclosureSEC source: 0000950170-24-111052 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 23:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 415 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111052 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · Custodial Account for Child Disclosed balance after: 9,665 F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| September 27, 2024 Filed Oct 1, 2024 23:55 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 415 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111052 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Indirect · Custodial Account for Child Disclosed balance after: 9,665 F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 22:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 7,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-108226 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 0 F2 · kind: These shares were transferred from the custodial account to the child's personal account. F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| September 18, 2024 Filed Sep 19, 2024 22:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 870 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-108226 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,772 F1 · balance_after: Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 17, 2024 Filed Sep 19, 2024 22:34 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-108226 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,642 F1 · balance_after: Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 503 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-104192 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,942 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 503 | $34.26 | $17,232.78 |
DisclosureSEC source: 0000950170-24-104192 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,439 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 3, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:57 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 254 | $35.30 | $8,966.20 |
DisclosureSEC source: 0000950170-24-104192 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,936 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on August 30, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 21:59 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 3,101 | $35.71 | $110,736.71 |
DisclosureSEC source: 0000950170-24-101501 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,190 F1 · balance_after: Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 11,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-24-081594 · ownership.xml · derivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,037 Underlying: Common Stock · 11,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 11,000 | $32.49 | $357,390.00 |
DisclosureSEC source: 0000950170-24-081594 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,291 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction. F1 · balance_after: Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 11,000 | $3.29 | $36,190.00 |
DisclosureSEC source: 0000950170-24-081594 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 22:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 550 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076962 · ownership.xml · nonDerivative · entry 5 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 9,250 F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 22:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 550 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076962 · ownership.xml · nonDerivative · entry 4 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 9,250 F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 22:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 550 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076962 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 7,250 F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 22:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076962 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Custodial Account for Child Disclosed balance after: 6,700 F2 · kind: These shares were transferred from the custodial account to the child's personal account. F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian. Read SEC document |
| June 24, 2024 Filed Jun 24, 2024 22:47 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 2,650 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076962 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,291 F1 · balance_after: Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 22:21 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 14,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-24-070045 · ownership.xml · derivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,037 Underlying: Common Stock · 14,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 22:21 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 8,174 | $32.87 | $268,679.38 |
DisclosureSEC source: 0000950170-24-070045 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,941 F2 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of options that occurred on June 4, 2024. The options subject to the net exercise were to expire on February 18, 2025. F1 · balance_after: Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 22:21 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 14,000 | $3.29 | $46,060.00 |
DisclosureSEC source: 0000950170-24-070045 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, and 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,818 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-069612 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,115 F6 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F3 · balance_after: Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 1,818 | $31.30 | $56,903.40 |
DisclosureSEC source: 0000950170-24-069612 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,297 F4 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 3, 2024. F5 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F3 · balance_after: Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 01:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 724 | $30.17 | $21,843.08 |
DisclosureSEC source: 0000950170-24-069612 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,479 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · price: The closing price on May 31, 2024 was used to calculate the withholding obligation. F3 · balance_after: Includes 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 28, 2024 Filed May 31, 2024 01:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock option (right to buy) · Derivative | 11,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0000950170-24-066889 · ownership.xml · derivative · entry 6 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,037 Underlying: Common Stock · 11,000 shares Expires 2025-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 28, 2024 Filed May 31, 2024 01:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 11,000 | $30.39 | $334,294.40 |
DisclosureSEC source: 0000950170-24-066889 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,203 F2 · kind: The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction. F3 · price: Represents the weighted average sale price for entire number of shares sold. The actual sale prices range from $29.25 to $32.00. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F1 · balance_after: Includes 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| May 28, 2024 Filed May 31, 2024 01:00 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 11,000 | $3.29 | $36,190.00 |
DisclosureSEC source: 0000950170-24-066889 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, and 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 697 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026707 · ownership.xml · nonDerivative · entry 3 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,203 F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. F2 · balance_after: Includes 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantCommon Stock | 697 | $24.06 | $16,769.82 |
DisclosureSEC source: 0000950170-24-026707 · ownership.xml · nonDerivative · entry 2 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,506 F3 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2024. F4 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. F2 · balance_after: Includes 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:41 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 656 | $24.06 | $15,783.36 |
DisclosureSEC source: 0000950170-24-026707 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,809 F1 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units. F2 · balance_after: Includes 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, and 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 00:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $23.01 | $0.00 |
DisclosureSEC source: 0000950170-24-014853 · ownership.xml · derivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-02-09 F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 9, 2024 over a four-year period. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 23:21 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-071652 · ownership.xml · nonDerivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,640 F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.